Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 7688 results

  1. Bed frames for adults in acute settings

    In development [GID-HTE10050] Expected publication date: 28 May 2025

    Health technology evaluations
    In development

  2. Lifileucel for previously treated unresectable or metastatic melanoma ID3863

    In development [GID-TA10752] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia TSID 12043

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073

    In development [GID-TA10959] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  5. Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]

    In development [GID-TA11277] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  6. Intermittent urethral catheters for urinary management in adults : Late Stage Assessment

    In development [GID-HTE10049] Expected publication date: TBC

    Health technology evaluations
    In development

  7. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development [GID-TA10981] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  8. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]

    In development [GID-TA11571] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  9. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development [GID-TA11140] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  10. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development [GID-TA11554] Expected publication date: 12 November 2025

    Technology appraisal guidance
    In development

  11. BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]

    Awaiting development [GID-TA11552] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development [GID-TA11023] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  13. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  14. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development [GID-TA11338] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development